Month Year
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Month Year
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Oct 18, 2021- Former Chief Scientific Officer and Head of Tumor Biology at Pfizer will lead IDEAYA's research organization as Chief Scientific Officer
-
Aug 10, 2021- Strong balance sheet of ~$400 million cash, cash equivalents and marketable securities is anticipated to fund planned operations into 2025
-
Jun 28, 2021‒ Observed plasma SAM reduction in each of the first two dose escalation cohorts of the IDE397 Phase 1 clinical trial, satisfying the clinical protocol threshold of approximately 60% or greater plasma S-adenosyl methionine (SAM) pharmacodynamic (PD) reduction to initiate IDE397 tumor biopsy cohort for evaluation of tumor PD markers